Accessibility StatementSkip Navigation SUMMIT, N.J., Oct. 21, 2025 /PRNewswire/ --Â CSL Seqirus, a business of CSL (ASX: CSL), announced recent data showing that cell-based influenza vaccines offer greater protection in preventing test-confirmed influenza compared to standard egg-based vaccines in a study among individuals six months to 64 years of age. "These data from the 2023/24 season show the clinical benefit of cell-based influenza vaccines over standard egg-based vaccines, and they continue to be rel ...